AtriCure, Inc. (NASDAQ:ATRC) Receives $50.89 Consensus Price Target from Analysts

Key Points

• AtriCure, Inc. has received a consensus rating of "Buy" from nine research firms, with an average one-year target price of $50.89.
• Insider trading activity includes significant sales by executives, resulting in a 3.36% decrease in insider ownership for Vinayak Doraiswamy and a 6.78% decrease for Regina E. Groves.
• In the most recent quarter, AtriCure reported revenue of $136.14 million, exceeding analysts' expectations, and narrowed its earnings per share guidance for FY 2025 to between -0.390 and -0.340.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been given an average recommendation of "Buy" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $50.8889.

Several equities analysts have weighed in on ATRC shares. Needham & Company LLC raised their target price on shares of AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, July 30th. Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, BTIG Research set a $54.00 target price on shares of AtriCure in a report on Wednesday, July 30th.

AtriCure Price Performance

Shares of NASDAQ ATRC traded down $0.23 during midday trading on Tuesday, hitting $36.43. The company had a trading volume of 676,041 shares, compared to its average volume of 415,295. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. AtriCure has a twelve month low of $25.57 and a twelve month high of $43.11. The business has a 50-day simple moving average of $34.76 and a two-hundred day simple moving average of $33.42. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -47.31 and a beta of 1.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The firm had revenue of $136.14 million during the quarter, compared to analysts' expectations of $130.17 million. During the same quarter last year, the business earned ($0.17) earnings per share. The business's revenue for the quarter was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Equities research analysts anticipate that AtriCure will post -0.6 earnings per share for the current year.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Regina E. Groves sold 2,452 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the transaction, the director directly owned 33,715 shares in the company, valued at approximately $1,241,386.30. This trade represents a 6.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Justin J. Noznesky sold 3,000 shares of AtriCure stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $36.30, for a total transaction of $108,900.00. Following the sale, the insider owned 83,964 shares of the company's stock, valued at approximately $3,047,893.20. This trade represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,952 shares of company stock valued at $655,633. Insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On AtriCure

Hedge funds and other institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the second quarter worth about $37,000. First Horizon Advisors Inc. grew its holdings in shares of AtriCure by 135.3% during the first quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company's stock worth $47,000 after buying an additional 832 shares in the last quarter. US Bancorp DE grew its holdings in shares of AtriCure by 98.1% during the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company's stock worth $51,000 after buying an additional 789 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of AtriCure during the fourth quarter worth about $60,000. Finally, State of Wyoming grew its holdings in shares of AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after buying an additional 446 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.